替考拉宁在肾功能不全及采用连续肾脏替代疗法患者中个体化用药的研究进展

替考拉宁作为糖肽类抗菌药，在治疗革兰阳性菌感染疾病方面发挥重要作用。但在临床应用中，其负荷剂量不当会导致治疗无效或产生不良反应，尤其对于肾功能不全及采用连续肾脏替代疗法（CRRT）的患者，替考拉宁的药动学/药效学（PK/PD）参数发生显著变化，且个体差异较大，干扰了临床给药剂量的精准，导致无法达到理想的疗效。因此，通过探讨替考拉宁在老年、儿童、低蛋白血症、体外膜肺氧合（ECMO）及行不同CRRT模式的肾功能不全患者体内PK特征与疗效的相关性，对替考拉宁的用药方案进行了综述，为临床个体化用药提供参考。

Advances in research on individualized administration of teicoplanin in patients with renal insufficiency and CRRT

Teicoplanin, as a glycopeptide antimicrobial, plays an important role in the treatment of gram-positive bacteria. However, in clinical applications, improper loading dose leads to ineffective treatment or adverse reactions. Especially for patients with renal insufficiency and continuous renal replacement therapy (CRRT), the pharmacokinetics/pharmacodynamics (PK/PD) parameters of teicoplanin change significantly, and the individual differences are large, which interferes with the accuracy of clinical administration and leads to the inability to achieve the desired therapeutic effect. Therefore, by exploring the correlation between the pharmacokinetic characteristics and efficacy of teicoplanin in elderly patients, children, hypoproteinemia, extracorporeal membrane oxygenation (ECMO) and renal insufficiency patients with different CRRT modes, this article reviews the medication regimen of teicoplanin on the basis of a large number of literature and theory, so as to provide a reference for clinical individualized medication.